Abstract
surgery versus RTX showed irrespective of the margin status a clear local control benfit for the addition of RTX in the range of 15−20%. Moreover, the improvement of post-RTX recurrence rates from 20−30% for total doses of 50Gy suggests an underlying dose-effect relationship. However, a recent study showed no benefit for dose escalation >56Gy except for increased rates of late complications. An EORTC study addressing RTX for progressive disease closed in 2008, whose results are still pending. The oral paper will collect the current evidences for multimodal treatment including adjuvant, neoadjuvant or definitive radiation for desmoid tumours hitherto.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
